Norrin is a ligand for Frizzled 4, or FZD4, a cell-surface receptor that works with tetraspanin 12 and LRP5 to regulate blood-vessel development and the integrity of the blood–brain and inner blood–retina barriers. Disrupted Norrin signaling has been associated with retinal disease, blood–retina barrier defects and deafness. The study, reported in Nature Structural & Molecular Biology, focuses on the molecular mechanism by which the signaling complex forms rather than on treatment outcomes in patients.

Determining the structure was challenging because the assembly depends on several interacting proteins. The researchers used a de novo designed FZD4 cysteine-rich-domain binder as a molecular “glue,” allowing them to capture and determine the structure of a Norrin–FZD4–TSPAN12–LRP5 complex. The structure shows that Norrin acts as a curved dimer that bridges receptor-containing units. It is not simply a solitary ligand contacting FZD4, but part of a larger assembly organized through multivalent interactions.

LRP5LA3 occupies a central coordinating position in the resolved complex. It interacts simultaneously with TSPAN12 and the two Norrin homodimers, helping position the cytosolic FZD4 and LRP5 tails for signal activation. The findings therefore connect the extracellular geometry of the complex with the intracellular signaling machinery. They also establish a physical model for how binding among Norrin, FZD4, TSPAN12 and LRP5 can bring receptor tails together without requiring all contacts to occur within a single protein pair.

Building on the structure, the researchers designed bispecific binders combining the FZD4 cysteine-rich domain with the LRP5LA3 domain. These engineered proteins function as Norrin surrogates in signaling assays, and their potency increased when the surrogate molecules oligomerized. The result indicates that multivalent assembly is not only a feature of the natural complex but can also improve the activity of engineered mimics. The study provides a structure-guided route for developing Norrin or Wnt mimetics, although the reported evidence comes from molecular structural analysis and signaling assays rather than demonstration of clinical benefit.

Subject of Research: Structural mechanism and engineering of the Norrin–FZD4–TSPAN12–LRP5 signaling complex

Article Title: Architecture of the Norrin signaling complex and structure-guided surrogate design

Article References: Hu, Q., Li, D., Long, T., Sun, Y., Junge, H. J., Schmiege, P., & Li, X. (2026). Architecture of the Norrin signaling complex and structure-guided surrogate design. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01909-1

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01909-1

Keywords: Norrin signaling, Frizzled 4, LRP5, tetraspanin 12, protein structure, protein engineering, bispecific binders, signal transduction, Architecture, Norrin, signaling, complex

EGFR is a receptor tyrosine kinase that sits on the cell surface and, when activated by its ligands, triggers cascades of intracellular signaling. The review’s schematic of EGFR downstream signaling illustrates the scope of its influence: pathways such as RAS–RAF–MEK–ERK and PI3K–AKT–mTOR radiate from the activated receptor, governing processes that cancer cells depend upon for proliferation, survival, migration and metastatic spread. When EGFR is overexpressed, as it frequently is in TNBC and inflammatory breast cancer, these pathways can become constitutively hyperactive, driving aggressive tumor behavior and resistance to apoptosis. On paper, this makes EGFR an obvious drug target—and indeed, EGFR inhibitors have transformed the treatment of other cancers, most notably lung carcinomas harboring activating EGFR mutations.

Yet in TNBC, the story has been far more sobering. Anti-EGFR antibodies and tyrosine kinase inhibitors, tested alone in clinical studies, have produced limited benefit. The review identifies several intertwined reasons. First, TNBC is not one disease but a constellation of molecularly distinct subtypes, and EGFR expression varies dramatically across them. Second, patient selection in past trials has often failed to stratify tumors by EGFR status or downstream pathway dependence, diluting any signal that might exist in EGFR-driven tumors. Third, cancer cells deploy an arsenal of resistance mechanisms—receptor mutations, compensatory signaling through parallel receptors, and alterations in downstream effectors—that allow tumors to circumvent a single blocked node in the network.

The subtype heterogeneity finding is particularly consequential for how future trials might be designed. According to the review, EGFR expression is highest in the basal-like 1 and 2 (BL1/2) subtypes of TNBC, followed by the mesenchymal and mesenchymal stem-like subtypes, with the immunomodulatory and luminal androgen receptor subtypes showing comparatively lower levels. This gradient matters because it implies that EGFR-directed therapy is unlikely to be a one-size-fits-all proposition. A tumor belonging to the BL1 subtype, with abundant receptor at its surface and strong signaling flux through growth-promoting pathways, may respond very differently from a luminal androgen receptor tumor in which EGFR plays a peripheral role. The practical implication is that molecular profiling—determining not just receptor abundance but the functional state of the signaling network—should precede any decision to deploy EGFR-targeted treatment.

Perhaps the most forward-looking element of the review is its case for co-targeting: pairing EGFR inhibition with simultaneous blockade of other molecules that participate in tumor progression, proliferation and metastasis. The authors analyzed transcriptomic data from EGFR-high and EGFR-low TNBC samples and identified 96 genes with substantially elevated transcription in the EGFR-high group. Among the candidates highlighted as potential co-targets are FABP4, a fatty acid binding protein implicated in metabolic adaptation; MMP9 and MMP14, matrix metalloproteinases that remodel the extracellular matrix and facilitate invasion; VCAM1, an adhesion molecule involved in metastatic trafficking; CCN4, a matricellular protein associated with tumor-stroma interactions; and CDK4/6, cell-cycle kinases whose inhibitors have already proven effective in hormone receptor-positive breast cancer.

The logic of this multi-target approach is rooted in the architecture of cellular signaling networks. A tumor cell that can reroute its survival signals through alternative pathways when EGFR is blocked becomes resistant to monotherapy. But if EGFR and a downstream or parallel node—say, CDK4/6 at the cell-cycle checkpoint, or MMP14 at the invasive front—are inhibited at the same time, the escape routes narrow dramatically. Co-targeting can also produce synergistic effects, where the combined inhibition is greater than the sum of individual effects, potentially allowing lower doses of each agent and thereby reducing the toxicity that has plagued combination regimens with conventional delivery.

This is where nanotechnology enters the picture. Delivering two or more therapeutic agents to the same tumor cells, at controlled ratios and with minimal exposure of healthy tissue, is one of pharmacology’s most stubborn challenges. Nanocarriers—including liposomes, dendrimers and other engineered nanoparticles—offer a solution that conventional formulations cannot match. Liposomes, spherical vesicles with aqueous cores surrounded by lipid bilayers, can encapsulate both hydrophilic and hydrophobic payloads. Dendrimers, highly branched synthetic macromolecules, present multiple functional groups on their surfaces for conjugating drugs, targeting ligands and imaging agents. Both platforms can be engineered to carry combinations of monoclonal antibodies, tyrosine kinase inhibitors and small interfering RNAs (siRNAs)—the last of which allows direct genetic silencing of targets such as MMP9 or FABP4 that are otherwise difficult to drug.

The advantages of nanocarrier delivery extend well beyond simple co-encapsulation. Nanoparticles can improve the pharmacokinetic profile of therapeutic agents, protecting fragile payloads such as siRNA from rapid degradation in the bloodstream and extending circulation time. Enhanced permeability and retention effects in tumor tissue, together with active targeting ligands that bind receptors on cancer cells, can increase tumor specificity and bioavailability at the disease site while sparing healthy organs. Crucially, co-loading ensures that the multiple agents arrive at the same cellular target site together, maintaining the synergistic ratios that co-targeting strategies depend upon—a level of spatial and temporal coordination that is nearly impossible to achieve with separately administered free drugs.

The review is careful to frame EGFR co-targeting as a promising direction rather than a near-term clinical reality. Appropriate molecular signatures must first be identified and rigorously validated to determine which patients will benefit, and delivery systems must demonstrate safety and efficacy in preclinical and clinical testing. The history of EGFR-targeted therapy in TNBC stands as a cautionary reminder that biological plausibility alone does not guarantee clinical success. But the integration of careful tumor classification, rational multi-target selection grounded in transcriptomic analysis, and nanocarrier-based delivery represents a coherent strategy for addressing the three failure modes—heterogeneity, poor patient selection and resistance—that have undermined earlier efforts.

For patients with aggressive EGFR-positive TNBC, the stakes could hardly be higher. If the precision framework outlined in this review matures into validated clinical protocols, the era of treating triple-negative breast cancer with blunt chemotherapy alone may give way to an approach in which a tumor’s molecular fingerprint dictates a tailored combination of inhibitors and gene-silencing agents, delivered together in a single nanoscale package. It is a vision that unites cancer genomics, network pharmacology and materials science—and one that could finally turn one of oncology’s toughest adversaries into a tractable, precisely targeted disease.

Subject of Research: EGFR co-targeting and nanocarrier-based drug delivery strategies for triple-negative breast cancer treatment

Article Title: Rethinking triple-negative breast cancer treatment through EGFR co-targeting and nanotechnology

Article References: Rethinking triple-negative breast cancer treatment through EGFR co-targeting and nanotechnology. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: triple-negative breast cancer, EGFR, co-targeting, nanocarriers, liposomes, dendrimers, siRNA, tyrosine kinase inhibitors, tumor heterogeneity, precision medicine, drug delivery, signal transduction

The work builds on a well-known fact of microbial life: microorganisms in nature rarely live alone. In the human gut, the Human Microbiome Project identified roughly 3,000 bacterial species coexisting in a single ecological niche, and their stability depends on constant chemical conversation. When antibiotics or dietary shifts disturb this balance, cross-feeding structures and nutrient competition shift with them, sometimes with severe health consequences. Understanding and eventually engineering such communication is therefore not just an academic curiosity — it is a prerequisite for designing stable synthetic microbial communities for industry, agriculture, and medicine.

Previous efforts had already pushed the boundaries of artificial cross-species signaling. In 2013, researchers showed that Escherichia coli could be made to talk to Bacillus megaterium using quorum-sensing peptides borrowed from Staphylococcus aureus. More recently, the Dresden group demonstrated communication in the opposite direction: yeast engineered to produce bacterial quorum-sensing peptides CSF and PhrF successfully activated reporter responses in B. subtilis. What remained missing was the reverse channel — bacteria signaling to yeast — and that is precisely what the new study delivers.

The engineering strategy exploited one of the most thoroughly characterized signaling systems in eukaryotic biology: the yeast mating pheromone pathway. Haploid Saccharomyces cerevisiae cells exist as one of two mating types, a or α, and each secretes a small peptide pheromone that binds to a specific receptor on cells of the opposite type. Receptor activation triggers a signaling cascade that induces morphological changes, cell-cycle arrest, and the expression of mating-specific genes. Among these, the FIG1 gene is switched on roughly 100-fold within just 20 minutes of receptor activation — a speed and dynamic range that makes it an ideal handle for synthetic biologists.

To turn B. subtilis into a yeast-language speaker, the team built on a signal peptide toolbox they had developed previously. The codon-optimized α-factor gene was inserted into an evaluation vector, preceded by the secretion signal peptide of the bacterial protein YfkD to route the peptide through B. subtilis’s native Sec secretion system. Expression was placed under the control of P_liaI, a promoter inducible by the antibiotic bacitracin. The final construct was integrated into the amyE locus of the protease-deficient strain WB800N, yielding the producer strain TMB6428. When induced with bacitracin, this strain secreted α-pheromone at concentrations of up to 8 nanomolar — modest by industrial standards, but consistent and robust, and sufficient for the task at hand.

On the receiving end, the researchers used a haploid yeast strain carrying deletions in BAR1 and FAR1. BAR1 encodes an aspartyl protease that degrades and inactivates α-factor, so its removal prevents the secreted signal from being destroyed before it can act. FAR1 encodes a cyclin-dependent kinase inhibitor responsible for the G1 growth arrest that normally follows pheromone exposure; deleting it keeps the sensor cells alive and dividing rather than frozen in mating mode. Into this background, the team integrated a single genomic copy of the fluorescent protein mNeongreen under control of the α-inducible FIG1 promoter. Genomic integration was necessary because B. subtilis cannot grow properly in yeast minimal medium, which would have made plasmid selection by auxotrophy impractical. The choice of mNeongreen over standard GFP was deliberate: originally discovered in the lancelet Branchiostoma lanceolatum, mNeongreen is the brightest green fluorescent protein known, resists photobleaching better than GFP, and matures faster — all advantages when the expected signal is weak.

Getting the two organisms to grow together posed its own challenges. B. subtilis doubles roughly every 30 minutes, while haploid yeast needs about 90 minutes in rich medium, so the team had to balance starting densities carefully. They settled on a ratio of approximately 1:6, with yeast at an OD600 of 0.1 and bacteria at 0.6 — a bias toward the bacterial producer that compensates for the fact that the engineered strain secretes only a single copy of α-factor, whereas yeast’s native MFα gene encodes four tandem copies processed into four separate peptides. The cultivation medium also required compromise: standard LB broth supplemented with 2% glucose satisfied the nutritional needs of both organisms at a shared incubation temperature of 31.5 °C.

The proof of principle came when mid-exponential co-cultures were induced with bacitracin. Within two hours, Western blot analysis detected mNeongreen protein in co-cultures containing the α-factor-producing bacteria, and the signal intensified at four and twenty-two hours as pheromone accumulated. Flow cytometry of 20,000 cells per sample confirmed statistically significant fluorescence in induced co-cultures, while negative controls — uninduced cultures and co-cultures with wild-type B. subtilis W168, which cannot produce α-factor — showed no detectable signal. The positive control, yeast treated with 250 nanomolar synthetic α-factor, produced brighter fluorescence than the co-culture, consistent with the bacterial secretion rate being lower than the bolus concentration used artificially. Under physiological conditions, 100 nanomolar synthetic α-factor is sufficient to induce mating in BAR1-deleted yeast, so the bacterial output, though modest, falls within a biologically meaningful range.

Perhaps the most visually striking evidence came from epifluorescence microscopy. Beyond the green glow of mNeongreen, the microscope revealed yeast cells undergoing shmoo formation — the characteristic pear-shaped morphological change that haploid cells adopt in response to authentic mating pheromone. Shmoo formation appeared about four hours after induction and increased over the following eighteen hours, demonstrating that the α-factor secreted by B. subtilis was not merely recognized at the receptor level but was fully functional, capable of driving the complete physiological differentiation program of yeast mating. The bacterial cells, meanwhile, showed no morphological changes, confirming that the signal flowed in one direction only.

The study also revealed a manageable imperfection: the P_liaI promoter exhibits slight leakiness, producing faint fluorescence in uninduced co-cultures after four and twenty-two hours. The researchers attribute this to known intrinsic transition-state induction of the LiaRS system, and note that the yeast-only positive control did not show this time-dependent increase because synthetic α-factor was added only once at the start rather than continuously. Looking ahead, the team envisions a synthetic sensor-actuator circuit in which engineered B. subtilis cells detect environmental signals — antibiotics, for example — and respond by secreting yeast pheromones that trigger the production of degradation enzymes in yeast. Since engineered S. cerevisiae capable of degrading β-lactam antibiotics in response to α-pheromone has already been described, the two pieces of such a self-regulating loop already exist. With accumulation of degradation end products potentially serving as a built-in negative feedback to shut the circuit down, the prospect of autonomous, self-contained microbial consortia — communicating across kingdoms to clean up pollutants or produce chemicals sustainably — has moved measurably closer to reality.

Subject of Research: Engineered interkingdom pheromone signaling between Bacillus subtilis and Saccharomyces cerevisiae

Article Title: Interkingdom communication 2.0: pheromone-based control between Bacillus subtilis and Saccharomyces cerevisiae

Article References: Döring, J., Vološen, T., Ostermann, K., & Wolf, D. (2026). Interkingdom communication 2.0: pheromone-based control between Bacillus subtilis and Saccharomyces cerevisiae. Applied Microbiology and Biotechnology, 110(1), Article 310. https://doi.org/10.1007/s00253-026-14069-5

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14069-5

Keywords: interkingdom communication, Bacillus subtilis, Saccharomyces cerevisiae, pheromone signaling, synthetic biology, quorum sensing, mNeongreen, co-culture, FIG1 promoter, microbial consortia, biotechnology, signal transduction

Long non-coding RNAs, or lncRNAs, are RNA molecules longer than roughly two hundred nucleotides that are transcribed from the genome but are not translated into proteins. For decades they were dismissed as transcriptional noise, yet it is now clear that many of them perform sophisticated regulatory duties inside cells. Some act as molecular scaffolds, bringing proteins together into functional complexes; others serve as guides, escorting proteins to specific DNA regions; still others function as sponges that soak up microRNAs. In cancer biology, lncRNAs have emerged as master regulators that can tilt the balance between cell growth and cell death, and between tissue stability and invasive spread. The Suzhou-led team set out to determine whether ATP6V1B1-AS1, an lncRNA named for its genomic neighbor in the ATP6V1B1 gene region, plays such a role in ovarian cancer.

To establish the clinical relevance of the molecule, the researchers first examined its expression pattern using data from The Cancer Genome Atlas, a large public repository of tumor genomic profiles, and then confirmed their observations in patient samples using reverse transcription quantitative polymerase chain reaction, a sensitive technique for measuring RNA abundance. The results were consistent: ATP6V1B1-AS1 was upregulated in ovarian cancer compared with normal tissue, and higher levels of the RNA were associated with worse prognosis in patients. This kind of correlation does not by itself prove causation, but it provided the essential starting hypothesis that the molecule might be doing something more than merely marking the presence of aggressive disease.

The team then moved from correlation to function. Using laboratory-grown ovarian cancer cells, they silenced ATP6V1B1-AS1 and measured the consequences with a battery of standard assays. Cell counting kit 8 assays, which quantify metabolic activity as a proxy for the number of living cells, showed that silencing the RNA slowed proliferation. Colony formation assays, which test whether single cells can divide repeatedly to form visible colonies, revealed a reduced capacity for sustained growth. Migration assays demonstrated that the cells also lost much of their ability to move, a property that is central to cancer’s ability to invade surrounding tissue and seed distant organs. Together, these in vitro experiments suggested that ATP6V1B1-AS1 is not a passive bystander but an active contributor to the malignant behavior of ovarian cancer cells.

To verify that these effects hold true in living organisms rather than only in culture dishes, the researchers turned to animal models. They used xenograft models, in which human ovarian cancer cells are implanted into immunodeficient nude mice, allowing human tumors to grow in a living host. They also established lung metastasis models to track the spread of cancer cells to secondary sites. When ATP6V1B1-AS1 was silenced, the mice developed smaller tumors and showed reduced metastatic colonization of the lungs. This in vivo confirmation is a critical step, because the three-dimensional architecture, nutrient gradients, and immune-free but otherwise complex environment of a living animal can expose dependencies that simple cell culture misses. The results indicated that the RNA’s influence on tumorigenesis and metastasis is robust enough to manifest in a whole organism.

With the functional role established, the central question became mechanistic: how does a non-coding RNA accomplish all of this? The team’s answer came from an unbiased search for binding partners. They performed an RNA pull-down experiment, in which the ATP6V1B1-AS1 molecule is used as bait to capture proteins that physically associate with it inside cells. The captured proteins were then identified by liquid chromatography coupled with tandem mass spectrometry, a technique that reads out the molecular weights and sequences of peptides to determine which proteins are present. Among the hits was MAP3K3, also known as MEK kinase 3, a mitogen-activated protein kinase kinase kinase that sits near the top of a signaling cascade controlling the p38 MAPK pathway, a route well known for transmitting stress and inflammatory signals into the cell nucleus.

The interaction between ATP6V1B1-AS1 and MAP3K3 was further validated by co-immunostaining and Western blotting, which confirmed that the RNA and the protein occupy overlapping cellular compartments and that their association has measurable biochemical consequences. Specifically, the binding of ATP6V1B1-AS1 to MAP3K3 facilitated the phosphorylation of p38 MAPK, the chemical modification that activates this pathway. Phosphorylation acts like a molecular switch: when p38 MAPK is phosphorylated, it relays signals that can promote cell survival, proliferation, and motility. Rescue experiments, in which the researchers restored pathway activity after silencing the RNA, demonstrated that the effects of ATP6V1B1-AS1 loss could be traced back through MAP3K3 to p38 MAPK, establishing a coherent signaling axis: ATP6V1B1-AS1 binds MAP3K3, MAP3K3 drives p38 MAPK phosphorylation, and the activated pathway propels ovarian cancer progression.

The significance of this work lies partly in its conceptual contribution to the growing recognition that lncRNAs can regulate cancer not only through gene expression but through direct protein interactions that modulate signaling cascades. Rather than changing how much MAP3K3 is produced, ATP6V1B1-AS1 appears to change what MAP3K3 does, enhancing its ability to activate p38 MAPK. This mode of action is attractive from a therapeutic standpoint because it suggests that disrupting the RNA-protein interaction, rather than blocking the kinase itself, might achieve a similar effect with potentially fewer off-target consequences. It also adds ATP6V1B1-AS1 to a short list of lncRNAs implicated in ovarian cancer, a disease that urgently needs new molecular targets given the limited treatment options available once platinum-based chemotherapy fails.

The research was supported by the Basic Research Medical Applied Basic Research Project in Suzhou City and the Suzhou Applied Basic Research Healthcare Science and Technology Innovation Guiding Project, and it received ethics approval from the Research Ethics Committee of Suzhou Municipal Hospital and the Animal Ethics and Welfare Committee of Nanjing Medical University. The authors, led by Yan Zhang, Ting Chen, and Meng Liu as co-first authors, with Shunyu Hou and Ting Fu as corresponding authors, declare no competing interests. As with any preclinical study, the path from these findings to the clinic will require further validation in larger patient cohorts and the development of strategies to safely interfere with the ATP6V1B1-AS1/MAP3K3/p38 MAPK axis in humans. Nevertheless, the study offers a clear mechanistic blueprint for how a single non-coding RNA can orchestrate tumor growth and metastasis, and it may provide a potential therapeutic target for ovarian cancer at a time when such targets are sorely needed.

Subject of Research: The role of the long non-coding RNA ATP6V1B1-AS1 in promoting ovarian cancer progression via the MAP3K3/p38 MAPK signaling pathway

Article Title: Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway

Article References: Zhang, Y., Chen, T., Liu, M., Zhang, Y., Zhou, L., Xi, X., Yu, L., Hou, S., & Fu, T. (2026). Long non-coding RNA ATP6V1B1-AS1 promotes ovarian cancer progression through targeting MAP3K3/p38 MAPK pathway. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02310-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02310-8

Keywords: ovarian cancer, long non-coding RNA, ATP6V1B1-AS1, MAP3K3, p38 MAPK, phosphorylation, metastasis, tumor progression, signal transduction, cancer biology, RNA-protein interaction, therapeutic target

The work, published in Nature Sensors by Boheng Yuan, Chen Li, Qinghai Meng, Yu-Guo Guo and colleagues at the Institute of Chemistry of the Chinese Academy of Sciences and the University of Chinese Academy of Sciences, with Bao Qiu of the Ningbo Institute of Materials Technology and Engineering, introduces what the authors call a dendrite-sensing composite solid electrolyte, or DSSE. The central idea is deceptively simple: instead of adding external sensors to monitor a battery’s health, the electrolyte itself becomes the sensor. It converts a microscopic chemical event — the first contact between a growing dendrite and the electrolyte — into a macroscopic electrical signal that appears in the external circuit, where any battery management system can read it.

The inspiration, the researchers say, comes from biology. Neurons do not need to be wired into every corner of the body to detect a stimulus; they transduce chemical and physical events at their membranes into electrical impulses that travel along nerves. In the same spirit, the composite electrolyte is designed with selective interfacial reactivity: it remains chemically quiet and electrochemically stable during normal cycling with the lithium anode, but it reacts selectively and detectably when it encounters penetrating lithium dendrites. That selectivity is the crux. Most electrolyte failures involve unwanted reactivity that degrades performance; here the team has deliberately engineered a material in which a specific, controlled reaction is reserved exclusively for the failure mode it is meant to detect.

Technically, the DSSE belongs to the family of composite solid electrolytes that combine inorganic ceramic ion conductors with polymer matrices, a class of materials widely pursued for solid-state batteries because it marries the high ionic conductivity of ceramics with the processability and interfacial compliance of polymers. The design challenge the team faced was twofold. First, the electrolyte had to support stable lithium plating and stripping — the back-and-forth motion of lithium ions that defines battery cycling — without itself being consumed. Second, it had to possess a built-in chemical trigger that fires only when lithium metal begins to penetrate the electrolyte body rather than merely sitting on its surface. Achieving both simultaneously required careful tuning of the composite’s composition and interfaces, and the authors report that the resulting material maintains stable anode cycling while retaining its dendrite-sensing capability.

The signal transduction mechanism is the most striking part of the study. When a dendrite reaches the sensing layer inside the electrolyte, the selective interfacial reaction alters the electrochemical state of the cell in a way that is registered in the external circuit as a characteristic voltage-based signal. In other words, the battery’s own voltage trace becomes a diagnostic readout. A battery management system that continuously monitors cell voltage — as essentially all commercial systems do — could in principle recognize this signature and flag the cell for inspection, derating or shutdown long before the dendrite completes its journey across the electrolyte and creates a hard short. The researchers demonstrate that this chemo-to-electrical transduction allows recognition of dendrite penetration before internal short circuits occur, which is precisely the window in which intervention can prevent thermal runaway.

This approach stands in sharp contrast to existing dendrite-detection strategies, which the paper’s extensive reference list makes clear is a crowded and creative field. Researchers have implanted flexible sensors into cells, used optical fibers with tilted fiber Bragg gratings to monitor dendrite formation operando, deployed printable multifunctional sensor arrays, captured hydrogen gas evolved by micro-scale dendrites as an early warning, and transmitted internal hazard signals wirelessly out of cells. Others have built smart polymer membranes that respond to risk, or thermo-responsive electrolytes that change behavior when heated. All of these methods share a common limitation: they rely on indirect signals such as temperature, pressure, strain or gas evolution, or they require invasive hardware placed inside the cell. Detecting heterogeneous dendrite growth directly, at the site where it happens, has remained a pivotal but elusive goal.

The DSSE sidesteps those limitations by making the sensing intrinsic to the battery’s core architecture. There are no additional components to manufacture, integrate or fail; the electrolyte is simultaneously the ion conductor and the nervous system of the cell. The authors describe this as a new paradigm of smart batteries using intrinsic sensing units, and they argue that the principle is universal: any interfacial reactivity that is normally considered a liability can, if it is made selective and well understood, be repurposed as a sensing opportunity. In the DSSE, the very chemical event that would herald catastrophe instead becomes the alarm bell. It is a conceptual inversion that could resonate well beyond lithium metal systems, wherever solid electrolytes face penetration by reactive metals.

The experimental evidence underpinning the claims is extensive. The published figures trace the full arc from biomimetic design concept through electrochemical performance, the transduction mechanism itself, and finally dendrite-sensing performance in complete smart lithium batteries. Supplementary materials include dozens of additional figures and notes, statistical source data for every main figure, and time-lapse optical and confocal laser imaging of the interface between a copper grid and the electrolyte, which allowed the team to watch the sensing process unfold in real time. The study also drew on density functional theory calculations to understand the interfacial chemistry, and distribution-of-relaxation-times analysis to interpret the electrochemical impedance signatures associated with dendrite contact.

The team behind the work is led by Yu-Guo Guo, a corresponding author and one of China’s most prominent battery scientists, together with co-corresponding author Qinghai Meng, both based at the CAS Key Laboratory of Molecular Nanostructure and Nanotechnology in Beijing. The project received support from the Strategic Priority Research Program of the Chinese Academy of Sciences, the National Key R&D Program of China, the National Natural Science Foundation of China and the Beijing Natural Science Foundation, among other funders. The paper was peer reviewed at Nature Sensors, with Guoxiu Wang and Jiangong Zhu among the reviewers acknowledged, and the authors declare no competing interests.

What happens next will determine whether dendrite-sensing electrolytes move from laboratory demonstrations to the cells in our cars and devices. The concept’s elegance lies in its compatibility: because the signal is electrical and appears at the terminals, it should be readable by existing battery management electronics without new sensor hardware, and because the material is a composite solid electrolyte, it slots into the same manufacturing pathways being developed for solid-state batteries more broadly. Real-world deployment will demand long-term cycling data, cost analysis at scale and validation across cell formats and operating conditions. But the conceptual advance is already significant. By transforming the electrolyte from a passive separator into an active, self-reporting component, the Beijing team has sketched a future in which batteries do not merely store energy — they know when something is going wrong inside them, and they say so in time to prevent the fire.

Subject of Research: A dendrite-sensing composite solid electrolyte that detects lithium dendrite penetration in batteries before short circuits occur

Article Title: A dendrite-sensing composite solid electrolyte for smart lithium batteries

Article References: Yuan, B., Li, C., Wang, Y.-H., Lv, Y., Xue, D.-J., Qiu, B., Wen, R., Meng, Q., & Guo, Y.-G. (2026). A dendrite-sensing composite solid electrolyte for smart lithium batteries. Nature Sensors. https://doi.org/10.1038/s44460-026-00145-w

Image Credits: AI Generated

DOI: 10.1038/s44460-026-00145-w

Keywords: lithium batteries, solid electrolyte, dendrites, thermal runaway, smart batteries, battery safety, composite electrolyte, signal transduction, solid-state batteries, battery management, Nature Sensors, energy storage

The significance of this perspective is difficult to overstate. KRAS mutations drive a substantial fraction of pancreatic, colorectal, and lung cancers, and for decades the protein was considered undruggable because of its smooth, featureless surface and its extraordinarily tight grip on GTP. Recent years have delivered the first direct inhibitors of mutant KRAS, but their impact has been limited to a specific mutation, G12C, and resistance has emerged rapidly in the clinic. The review’s central thesis is that the next wave of therapeutic opportunity may lie not in the nucleotide pocket itself but in the enzymes that install, read, and remove the chemical tags governing KRAS behavior. By targeting PTM machinery, researchers could in principle control KRAS output even when direct inhibition of the protein fails.

The first and best-characterized layer of this regulation concerns membrane localization. KRAS is a small GTPase that must sit at the inner face of the plasma membrane to encounter its activators and effectors, and its delivery there depends on a sequence of modifications at the carboxyl terminus. A farnesyl or geranylgeranyl lipid group is attached to the CaaX motif, the terminal peptide is cleaved, and the new C-terminus is carboxymethylated. Together these changes anchor the protein in membranes. Additional palmitoylation events, which differ among RAS isoforms, further refine trafficking routes through the Golgi and determine the specific membrane microdomains the protein occupies. The review emphasizes that this spatial organization is not a static address label but a continuously tuned system that shapes signaling output.

What makes this system therapeutically interesting is that every enzymatic step is a potential drug target. The farnesyltransferase inhibitors developed in the 1990s ultimately failed in clinical trials, in part because KRAS was rescued by alternative prenylation through geranylgeranyltransferase. Yet the field has learned from that experience, and the review suggests that modern strategies, including inhibitors of palmitoylation enzymes such as the DHHC acyltransferases and of depalmitoylation machinery, could recalibrate KRAS membrane association with greater precision. Because these enzymes act on the trafficking pathway rather than the nucleotide pocket, they may remain effective even against mutants that evade direct inhibitors.

Beyond localization, the review highlights a second layer of PTM control: the regulation of nucleotide cycling itself. KRAS activity depends on the balance between guanine nucleotide exchange factors, which load GTP, and GTPase-activating proteins, which accelerate hydrolysis back to GDP. Emerging evidence indicates that modifications such as phosphorylation, ubiquitination, and acetylation can tilt this balance by altering the protein’s conformation, its accessibility to regulators, or its interaction surfaces. In this view, the classical GDP/GTP switch is not an autonomous timer but a dial whose sensitivity is continuously adjusted by the cell’s modification state. Understanding how oncogenic mutations interact with these adjustments may explain why tumors with identical KRAS mutations can behave so differently.

A third layer concerns effector engagement. Once KRAS is GTP-bound, it recruits downstream effectors such as RAF kinases, PI3K, and RALGDS to transmit proliferative signals. The review notes that post-translational modifications can modulate the strength and duration of these interactions, effectively deciding which signaling branches dominate in a given cellular context. This has direct clinical relevance: resistance to KRAS inhibitors frequently arises through reactivation of downstream pathways, and if PTMs tune effector coupling, then targeting the modification enzymes could close those escape routes. The authors frame this as a strategy to overcome resistance in KRAS-driven cancers by attacking the regulatory network rather than a single protein-ligand interface.

Protein stability and degradation form a fourth pillar of the review’s argument. Ubiquitination, the attachment of ubiquitin chains, can mark KRAS for destruction by the proteasome, and deubiquitinating enzymes can rescue it. The lifetime of the KRAS protein within the cell is therefore not fixed but actively managed. Small-molecule approaches that exploit this, such as proteolysis-targeting chimeras designed to recruit degradation machinery to KRAS, represent one of the most actively pursued frontiers in the field. The review situates these degrader strategies within the broader PTM framework, arguing that the natural ubiquitination machinery of KRAS provides both a proof of principle and a set of enzymatic handles that degrader drugs could co-opt.

The authors also draw attention to the interplay among different modification types. Phosphorylation, ubiquitination, acetylation, methylation, and lipidation do not operate in isolation; each can influence the others, creating combinatorial codes that specify distinct functional states of the protein. This cross-talk means that inhibiting a single enzyme may produce cascading effects across the network, which is both an opportunity and a caution. The opportunity lies in the potential for lower-dose, network-level interventions that avoid the toxicity of complete KRAS ablation. The caution is that the network’s redundancy may allow cancer cells to compensate, underscoring the need for systematic mapping of modification sites and their functional consequences, which the review identifies as a priority for future research.

Methodologically, the work is a literature review, synthesizing findings from cell biological, structural, and pharmacological studies into a unified framework. The subject of the underlying research is cellular regulation, and the review’s scope spans the full life cycle of the KRAS protein, from its synthesis and membrane delivery to its activation, effector recruitment, and eventual degradation. By organizing this material around the concept of PTM-dependent regulation, the authors offer researchers a conceptual map for designing experiments and, ultimately, combination therapies that pair direct KRAS inhibitors with agents targeting modification enzymes. The review was published in the journal’s 2026 volume under DOI 10.55092/acr20260014.

The broader message for oncology is one of cautious optimism. KRAS-driven cancers remain among the most lethal malignancies, and the initial wave of direct inhibitors, while a historic milestone, has exposed the limits of targeting a single mutation in a single pocket. The PTM perspective reframes the problem: KRAS is not one target but a hub in a regulated network, and every node in that network is a potential point of therapeutic leverage. As the review concludes, targeting PTM enzymes and the modification-dependent regulatory networks they compose may provide new therapeutic opportunities and, critically, strategies to overcome the resistance that has so far blunted the impact of KRAS-directed therapy. For patients with pancreatic, lung, and colorectal cancers, that reframing could not come soon enough.

Subject of Research: Post-translational modifications regulating KRAS protein function and their therapeutic targeting in cancer

Article Title: Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting

Article References: Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: KRAS, post-translational modifications, oncogene, cancer therapy, membrane localization, ubiquitination, palmitoylation, drug resistance, GTPase, signal transduction, protein degradation, Advanced Cancer Research

The appeal of narciclasine lies in its pedigree. Alkaloids from the Amaryllidaceae family have attracted attention for decades because of their diverse pharmacological activities, ranging from anti-inflammatory effects to potent cytotoxicity against tumor cells. Previous work by other groups has shown that narciclasine can kill cancer cells by activating both the death receptor and mitochondrial apoptotic pathways, that it targets the translation elongation factor eEF1A in melanoma cells, and that it acts as a GTP-ase targeting agent against brain cancers. More recently, studies in esophageal, gastric, colon, oral, and breast cancers have implicated a variety of molecular mechanisms, from FAK inhibition to STAT3 suppression and topoisomerase I blockade. What remained poorly understood, however, was whether any of this activity extended to neuroblastoma, a tumor whose biology differs markedly from the adult carcinomas where most of this earlier work was performed.

To fill that gap, the research team, led by Ceren Oy and Sema Serter Kocoglu of the Department of Histology and Embryology, subjected SH-SY5Y cells, a widely used human neuroblastoma line, to a battery of assays designed to interrogate every hallmark of malignant behavior. Cell viability was quantified with the CCK-8 colorimetric assay, a sensitive readout of metabolic activity that has become a standard first screen for candidate drugs. The investigators tested a range of narciclasine concentrations and found that 50 and 100 nanomolar doses significantly reduced the viability of the neuroblastoma cells. Critically, when the same doses were applied to human umbilical vein endothelial cells, or HUVECs, a common non-malignant comparator, the cytotoxic effect was comparatively lower, an early hint that the compound might discriminate between tumor and healthy tissue, at least under the conditions tested.

With those two concentrations selected as the working doses, the team moved on to the central question of proliferation. Using immunofluorescence staining for Ki67, a nuclear protein expressed exclusively in actively dividing cells, they observed a marked decrease in the fraction of Ki67-positive neuroblastoma cells after narciclasine treatment. Proliferation is the engine of tumor expansion, and its suppression at such low drug concentrations is notable. The finding echoes earlier reports in esophageal cancer cells, where narciclasine was shown to curb proliferation through inhibition of the focal adhesion kinase, or FAK, signaling pathway, and it aligns with the broader literature on Amaryllidaceae alkaloids as cell cycle modulators.

Migration and metastatic potential were assessed next, using the wound-healing assay, in which a scratch is made across a confluent cell monolayer and the rate at which cells close the gap is measured as a proxy for motility. Narciclasine-treated cells closed the wound more slowly than untreated controls, indicating impaired migratory capacity. Colony formation assays reinforced the picture: the ability of individual cells to anchor independently and proliferate into visible colonies, a laboratory correlate of tumorigenic potential, was substantially reduced. For a cancer like neuroblastoma, whose clinical course is so often defined by metastatic spread, any agent that blunts motility in vitro is of considerable interest, particularly one that appears to act on the cytoskeletal and adhesion machinery through FAK.

The apoptotic results were equally striking. TUNEL staining, which detects the fragmented DNA characteristic of programmed cell death, revealed a significant increase in apoptotic cells following narciclasine exposure, and immunofluorescence for cleaved caspase-3, the executioner enzyme of apoptosis, showed correspondingly enhanced immunoreactivity. In parallel, the COMET assay, a single-cell gel electrophoresis technique that visualizes DNA strand breaks as a comet-like tail of migrated genetic material, demonstrated increased DNA damage in the treated cells. Together, these findings suggest that narciclasine pushes neuroblastoma cells toward a self-destructive fate while inflicting genotoxic stress that may itself contribute to the apoptotic signal.

The mechanistic core of the study lies in the FAK/PI3K pathway. Focal adhesion kinase is a cytoplasmic tyrosine kinase that integrates signals from cell adhesion receptors and growth factor pathways, and it is frequently overactive in aggressive tumors, including neuroblastoma, where prior work has shown that inhibiting FAK decreases tumor growth. Downstream of FAK, phosphoinositide 3-kinase, or PI3K, drives survival and growth signaling through the Akt axis, making the combined FAK/PI3K module a linchpin of malignant behavior. Using both immunohistochemistry and Western blot analysis, the Turkish team demonstrated that narciclasine treatment reduced the expression levels of both FAK and PI3K in the neuroblastoma cells, providing a coherent molecular explanation for the observed collapse in proliferation and migration.

This mechanism places the new findings within a rapidly growing body of literature on narciclasine’s anticancer pharmacology. In esophageal cancer, the compound suppresses proliferation and migration by inhibiting FAK signaling; in gastric cancer, it induces autophagy-mediated apoptosis through the Akt/mTOR pathway; in colon carcinoma, it triggers apoptosis by blocking the IL-17A/Act1/TRAF6/NF-κB cascade; and in tamoxifen-resistant breast cancer, it targets STAT3 through distinct mechanisms. A 2025 study further proposed narciclasine as a means of overcoming EGFR-TKI resistance in non-small cell lung cancer. The convergence of these reports on adhesion, survival, and inflammatory signaling pathways suggests that the alkaloid may act on a limited set of master regulators whose suppression is lethal to many tumor types, and the present study extends that logic to a pediatric solid tumor for the first time.

The clinical context makes the work timely. Neuroblastoma treatment has seen incremental advances, including anti-GD2 monoclonal antibody therapy and targeted agents, but toxicity remains a persistent concern, as illustrated by recent reports of pulmonary toxicity associated with combination regimens. Molecular targeting therapies for neuroblastoma have progressed, yet significant challenges persist, and the search for agents that are both effective and better tolerated continues. The observation that narciclasine exerted comparatively lower cytotoxicity against non-malignant HUVEC cells at the effective neuroblastoma doses is an early but encouraging sign of a therapeutic window, though the authors and outside observers alike would caution that in vitro selectivity is a far cry from clinical safety.

Indeed, the researchers themselves are careful to frame the study as a starting point rather than a conclusion. Their findings, they write, suggest that narciclasine exerts anti-neuroblastoma effects associated with reduced proliferative and migratory activity, increased apoptotic response, and modulation of FAK/PI3K-associated signaling in SH-SY5Y cells, but further studies are needed to clarify the precise molecular basis and therapeutic relevance of these effects. Key questions remain: whether the results hold in additional neuroblastoma cell lines, particularly MYCN-amplified high-risk variants; whether the compound is active in animal models of metastatic disease; how narciclasine’s known effects on translation elongation and other pathways interact with the FAK/PI3K axis; and whether pharmacokinetic and toxicity profiles can support eventual clinical testing in children. The work, supported by the Bursa Uludag University Scientific Research Projects Unit, was published on 29 August 2026 as an original paper in Medical Oncology, volume 43, article 261. For now, it stands as a compelling proof of concept that a molecule first isolated from the bulbs of an ornamental lily may one day inform new strategies against one of childhood’s most stubborn cancers.

Subject of Research: Effects of the plant alkaloid narciclasine on neuroblastoma cell proliferation, migration, apoptosis, and FAK/PI3K signaling

Article Title: Narciclasine reduces proliferation and migration of neuroblastoma cells and decreases FAK/PI3K pathway activation

Article References: Oy, C., Serter Kocoglu, S., Isıklar, S., & Gok Yurtseven, D. (2026). Narciclasine reduces proliferation and migration of neuroblastoma cells and decreases FAK/PI3K pathway activation. Medical Oncology, 43(10), Article 261. https://doi.org/10.1007/s12032-026-03359-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03359-7

Keywords: narciclasine, neuroblastoma, FAK/PI3K pathway, apoptosis, DNA damage, SH-SY5Y cells, Amaryllidaceae alkaloids, pediatric oncology, cell migration, Ki67, natural products, signal transduction

The Albany Prize has been awarded annually since 2001 and was established by the late Morris “Marty” Silverman, whose vision was to celebrate scientists whose work exemplifies the “bench to bedside” arc of modern biomedical research: fundamental discoveries made at the laboratory bench that ultimately translate into treatments that measurably improve the lives of patients across the country and around the globe. That mission is underwritten by a $50 million gift commitment from the Marty and Dorothy Silverman Foundation to Albany Medical Center, a commitment that guarantees the prize can be conferred for 100 years and has helped build its reputation to a level often described as approaching that of the Nobel Prize. Past recipients read like a roster of modern biomedical history, including former National Institute of Allergy and Infectious Disease director Anthony Fauci, CRISPR pioneers and Nobel Laureates Emmanuelle Charpentier and Jennifer Doudna, and mRNA vaccine pioneers and Nobel Laureates Katalin Karikó and Drew Weissman, among many others. Hunter’s inclusion in that company reflects the sheer reach of a single biochemical insight made more than four decades ago.

That insight concerns a molecular switch known as tyrosine phosphorylation. Phosphorylation, the process by which enzymes attach phosphate groups to amino acids within proteins, is one of the cell’s most fundamental control mechanisms, a way of flipping proteins between functional states in response to signals. For years, scientists knew that phosphate groups could be attached to the amino acids serine and threonine. What Hunter discovered in 1979, quite by accident, was that phosphate could also be linked to a third amino acid: tyrosine. The finding revealed an entirely new class of regulatory enzymes, the tyrosine kinases, which add phosphate groups to tyrosine residues and in doing so help govern how cells grow, divide, and communicate with their surroundings.

The discovery itself is a textbook example of serendipity rewarding careful observation. Hunter was conducting an experiment to separate the amino acids in a viral protein, a routine analytical procedure that depended on a buffer, a solution used to control acidity. Unknowingly, he used a buffer with a pH of 1.7 instead of the intended 1.9. That tiny difference in acidity, a shift of just two-tenths of a pH unit, altered the chemical behavior of the phosphorylated amino acid in his sample just enough to expose what had previously been hidden: a phosphate group sitting on a tyrosine residue. Had the pH been exactly as planned, the modification might have gone undetected. “A gratifying outcome of this set of experiments on a simple chicken tumor virus,” Hunter later wrote of the episode in a 2015 perspective published in the Proceedings of the National Academy of Sciences, a wry acknowledgment that a humble reagent error had opened a vast new field of cancer biology.

What followed the 1979 landmark study was a career of persistent, systematic elaboration. Hunter went on to write and publish many additional papers on this new protein kinase family, methodically characterizing how tyrosine kinases work and how they are controlled. Through that sustained curiosity, he came to a realization that would transform medicine: tyrosine kinases become overactive in many human cancers. When the molecular switches that regulate cell growth become stuck in the on position, cells proliferate uncontrollably. Identifying tyrosine phosphorylation therefore did more than add a line to biochemistry textbooks; it handed cancer researchers a specific, druggable target. If overactive tyrosine kinases drive malignancy, then molecules designed to block those enzymes might stop tumors in their tracks.

That logic produced one of the great success stories of modern oncology. In 2001, the U.S. Food and Drug Administration approved imatinib, known commercially as Gleevec, the first in a revolutionary class of drugs called tyrosine kinase inhibitors. Imatinib transformed the treatment of chronic myelogenous leukemia, converting what had been a terminal disease into a highly manageable condition for many patients. It was the proof of principle that Hunter’s foundational discovery could be turned directly into lifesaving therapy. Today, more than 100 cancer drugs that block overactive tyrosine kinases exist, all of them tracing their conceptual origin to Hunter’s identification and characterization of the tyrosine kinase family. Few basic science discoveries can claim a pharmacological legacy of that scale, and it is precisely this bench-to-bedside trajectory that the Albany Prize was created to honor.

Hunter shares the 2026 prize with Dennis Slamon of UC Los Angeles, whose own cancer biology discoveries have likewise translated into therapies with global impact. The pairing of the two laureates underscores a theme that runs through the Albany Prize’s history: the award seeks scientists whose laboratory insights have demonstrably reached patients. In Hunter’s case, the chain of translation runs from a chicken tumor virus experiment in 1979, through decades of enzymology and signal transduction research, to a pharmacopoeia of kinase inhibitors now deployed in clinics worldwide. Gerald Joyce, MD, PhD, president of the Salk Institute, praised Hunter’s approach to science in announcing the honor. “Tony’s dedication to curiosity-driven research has made him an irreplaceable asset at Salk and in science at large,” Joyce said. “His commitment to foundational discovery has transformed cancer biology and treatment, and we look forward to celebrating this honor with him.”

Remarkably, the discovery that anchors this award is not the endpoint of Hunter’s career but a chapter in its middle. The year 2025 marked his 50th at the Salk Institute, where he remains an active researcher, pursuing his own collaborations and projects while taking evident pride in training the next generation of cancer biologists and life sciences researchers. His perspective on the unfinished nature of biology is one he shares directly with his students. “When I’m teaching students, I say an awful lot has already been discovered, but an awful lot remains unknown. I’m sure that new biological principles will emerge that we can’t even imagine right now,” Hunter said in a 2023 feature in Inside Salk magazine. “I’m excited because there will always be new things to be discovered for as long as I’m alive.” It is a sentiment that captures the ethos of curiosity-driven research that colleagues credit for his longevity and productivity at the bench.

The Albany Prize adds a distinguished new item to an already crowded shelf of accolades. Hunter’s earlier honors include the Wolf Prize in Medicine, the Gairdner Foundation International Award, the Louisa Gross Horwitz Prize, the National Cancer Institute Outstanding Investigator Award, the American Association for Cancer Research Lifetime Achievement Award in Cancer Research, the Sjöberg Prize for Cancer Research, the Prince Mahidol Award, and the Dr. Paul Janssen Award for Biomedical Research. He has also been elected a fellow of the American Association for Cancer Research, a Member of the American Philosophical Society, a fellow of the Royal Society of London, a Member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and a Member of the National Academy of Medicine. Each of these recognitions, like the Albany Prize itself, circles back to the same origin: a two-tenths-of-a-pH-unit error in 1979 that revealed how a phosphate group on a single amino acid could unlock the molecular logic of cancer, and ultimately the drugs that hold it in check for millions of patients.

Subject of Research: Recognition of Tony Hunter's discovery of tyrosine phosphorylation and its role in targeted cancer drug development

Article Title: Salk scientist Tony Hunter receives 2026 Albany Prize

Article References: Salk scientist Tony Hunter receives 2026 Albany Prize. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Tony Hunter, Albany Prize, tyrosine phosphorylation, tyrosine kinases, cancer drugs, imatinib, Gleevec, Salk Institute, chronic myelogenous leukemia, signal transduction, biomedical research award, Dennis Slamon

The protein, known as TSPAN32, belongs to the tetraspanin family, a group of four-pass transmembrane proteins that organize other surface receptors into functional microdomains on the cell membrane. Tetraspanins have long been recognized as molecular scaffolds, clustering receptors and signaling molecules to fine-tune how cells respond to their environment. What distinguishes the new work is the discovery that TSPAN32 does something particularly consequential in T cells: it assembles the interleukin-2 receptor complex at the cell surface and strengthens the signals that flow from it into the cell’s interior, thereby amplifying one of the most important growth and survival pathways in immunology.

The investigators began with a clinical observation. When they examined T cells isolated from the peripheral blood of patients with B-cell lymphoma, they found that TSPAN32 expression was consistently reduced compared with T cells from healthy donors. This depletion was intriguing because TSPAN32 had previously been implicated in immune regulation, with earlier studies documenting its modulation during T cell-mediated immune responses and in autoimmune conditions such as multiple sclerosis. Previous work by some of the same collaborators had also shown that TSPAN32 can suppress chronic myeloid leukemia by stabilizing the tumor suppressor PTEN, hinting that the protein plays meaningful roles in cancer biology from multiple angles.

To test whether restoring TSPAN32 could improve CAR-T cell performance, the team engineered T cells to co-express both a CD19-targeting chimeric antigen receptor and TSPAN32. In laboratory culture, the doubly engineered cells outperformed standard CD19 CAR-T cells on essentially every measure the researchers applied. They killed tumor cells more efficiently and produced higher quantities of cytokines, the chemical messengers through which T cells coordinate immune attacks. The enhanced activity was not a subtle effect; the addition of TSPAN32 shifted the engineered cells toward a more robust effector phenotype, the functional state associated with aggressive and sustained anti-tumor activity.

The therapeutic advantage held up in animal models. In subcutaneous tumor models, mice that received TSPAN32-enhanced CAR-T cells showed superior tumor control compared with mice receiving conventional CAR-T cells, demonstrating that the in vitro benefits translated into meaningful in vivo efficacy. Gene expression profiling using RNA sequencing provided a mechanistic clue: TSPAN32-high CAR-T cells displayed increased activation of IL-2 signaling pathways, suggesting that the tetraspanin was not merely a passive marker of T cell health but an active driver of the signaling circuits that sustain T cell proliferation and cytotoxic function.

The mechanistic studies went a step further by pinpointing the molecular partner through which TSPAN32 exerts its effects. The IL-2 receptor is composed of multiple subunits, including CD25, the alpha chain that captures interleukin-2 and initiates the signaling cascade upon ligand binding. The researchers found that TSPAN32 physically interacts with CD25 and promotes its aggregation on the T cell surface. This clustering matters because receptor aggregation can concentrate signaling components into membrane microdomains, effectively increasing the strength and efficiency of the intracellular signal that follows IL-2 engagement. In essence, TSPAN32 acts as a membrane-level organizer that ensures the IL-2 receptor complex is assembled and positioned for maximal signal transduction, allowing the T cell to extract more proliferative and activational benefit from the same amount of cytokine.

Two additional experimental systems strengthened the case that TSPAN32 is a legitimate therapeutic target rather than an artifact of overexpression. First, the team used a transgenic mouse model in which TSPAN32 was overexpressed endogenously in T cells. These animals showed increased resistance to subcutaneous tumor growth, indicating that physiological levels of elevated TSPAN32 are sufficient to confer protection. Second, and perhaps most provocatively, the researchers developed a TSPAN32-specific antibody designated FF-37. When administered, FF-37 increased TSPAN32 expression and improved the anti-tumor efficacy of CAR-T cells. The existence of an antibody that can pharmacologically upregulate the protein opens the door to approaches that do not require additional genetic engineering of the patient’s cells, which would simplify manufacturing and potentially reduce the cost and regulatory complexity associated with engineered cell therapies.

The significance of these findings lies in how they address one of the central bottlenecks in cellular immunotherapy: T cell exhaustion and functional decline. CAR-T cells often enter a state of progressive dysfunction in the tumor microenvironment, characterized by diminished cytokine production, impaired cytotoxicity, and the upregulation of inhibitory receptors. Because IL-2 signaling sits at the interface between tolerance and immunity, fine-tuning this pathway has been a long-standing goal in immunology, albeit a delicate one, since excessive IL-2 signaling can also fuel regulatory T cells that suppress immune responses or trigger systemic toxicity. By enhancing the assembly and signaling efficiency of the receptor complex at the membrane level rather than flooding the system with exogenous cytokine, TSPAN32 offers a mechanism for amplifying IL-2 pathway output in a manner that is intrinsic to the engineered cell itself.

The study, led by Yuanyuan Sun and Qiang Qiu, who contributed equally, with correspondence from Yiguo Hu of West China Hospital, Sichuan University, and supported by funding from the National Natural Science Foundation of China and regional Sichuan research programs, positions TSPAN32 as a candidate for the next generation of CAR-T cell optimization strategies. Whether genetic co-expression of TSPAN32 or antibody-mediated upregulation with FF-37 proves more practical in the clinic will depend on safety profiling and manufacturing considerations that lie ahead. But the conceptual advance is clear: the potency of engineered immune cells can be strengthened not only by changing what receptors they carry, but by reorganizing the membrane architecture through which their survival signals travel. If subsequent studies confirm these results in additional tumor models and, ultimately, in patients, a member of a protein family once regarded mainly as a structural scaffold may become one of the most sought-after enhancements in cellular cancer therapy.

Subject of Research: Enhancement of CAR-T cell anti-tumor potency through TSPAN32-mediated assembly of the IL-2 receptor complex and amplified IL-2 signal transduction.

Article Title: TSPAN32 enhances CAR-T cell potency by assembling IL-2 receptor complex and amplifying its intracellular signal transduction

Article References: Sun, Y., Qiu, Q., Wang, B., Feng, Y., Wang, J., Pan, C., Zheng, L., Qiu, H., He, W., Su, Z., Li, S., & Hu, Y. (2026). TSPAN32 enhances CAR-T cell potency by assembling IL-2 receptor complex and amplifying its intracellular signal transduction. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03592-x

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03592-x

Keywords: CAR-T cells, TSPAN32, tetraspanin, IL-2 signaling, CD25, B-cell lymphoma, cancer immunotherapy, FF-37 antibody, T cell exhaustion, signal transduction, CD19, cellular therapy

The drug targets the phosphatidylinositol-4,5-bisphosphate 3-kinase, AKT, mechanistic target of rapamycin signaling cascade, a central growth and survival pathway that is frequently dysregulated in both canine and human cancers. When this pathway runs amok, it drives neoplastic cells to proliferate relentlessly, evade apoptosis, crank up metabolism, and, in the case of lymphoid malignancies, stimulate the production of vascular endothelial growth factor, a molecule that supports tumor neovascularization. Because single-node inhibitors of the pathway often deliver only brief or incomplete responses, likely due to well-known feedback loops within the signaling network, the researchers turned to VDC597, a compound that blocks PI3K along with both mTOR complexes, mTORC1 and mTORC2, thereby hitting the pathway at multiple points simultaneously.

In their experiments, the team tested VDC597 against two canine cell lines: 1771, derived from a spontaneously occurring B-cell lymphoma, and CLL1390, derived from chronic lymphocytic leukemia. Both lines had previously been documented to carry mutations in or constitutively express activated proteins of the PI3K-AKT-mTOR pathway, making them appropriate models for pathway-targeted therapy. Western blot analysis showed that a 24-hour treatment with the drug produced a clear, dose-dependent reduction in phosphorylated AKT at the serine 473 residue, the molecular signature of pathway activation. The leukemia line proved more sensitive, showing significant suppression at concentrations as low as 0.2 micromolar, while the lymphoma line required a full micromolar dose to achieve statistically significant inhibition.

Timing experiments revealed that the drug’s effects on signal transduction are both rapid and durable. Following a single 1 micromolar dose, phosphorylation of AKT dropped quickly and remained at roughly half of control levels for a full 24 hours. Downstream phosphorylation of 4EBP1, a translation-regulating target of mTORC1, fell even more sharply, with statistically significant suppression measurable from half an hour after treatment through the two-hour mark. The researchers verified these biochemical findings by immunohistochemistry on fixed cell pellets, observing reduced perinuclear and cytoplasmic staining for both phosphoproteins after drug exposure, an encouraging confirmation that the compound shuts down signaling across the entire pathway rather than just a single branch.

The functional consequences were equally striking. After 72 hours of exposure, VDC597 halved the viable cell population at concentrations within or near what is pharmacologically achievable, with mean half-maximal inhibitory concentrations of 1.41 micromolar for CLL1390 and 2.56 micromolar for 1771, values informed by an earlier phase I trial of the drug in tumor-bearing dogs. Live-cell imaging, tracking fluorescently labeled nuclei and dead-cell stains over 48 hours, showed that the drug did not merely slow proliferation: it actively killed the lymphoma cells, with cell death increasing in a dose-dependent manner and becoming significantly elevated at concentrations of 0.25 micromolar and above. Enzyme-linked immunosorbent assays further demonstrated that VDC597 suppressed vascular endothelial growth factor production in both cell lines, again in a dose-dependent fashion, suggesting the drug may undermine the angiogenic support system that lymphoid tumors rely upon.

Because combination therapy, not single agents, ultimately determines how well targeted drugs translate into clinical benefit, the team paired VDC597 with the three chemotherapy drugs most commonly used in canine lymphoma protocols: dexamethasone, doxorubicin, and vincristine. The results were revealing. Combining VDC597 with dexamethasone produced genuinely synergistic growth inhibition, quantified by combination indices below 1 using the Chou-Talalay method, with the effect strongest at lower drug concentrations. Pairing the drug with doxorubicin yielded additive to mildly synergistic effects at lower doses, though the highest doxorubicin concentration produced antagonism, possibly because PI3K inhibition dampens the reactive oxygen species generation through which doxorubicin promotes apoptosis. Vincristine, whose mechanism overlaps with the pathway’s role in microtubule function during mitosis, showed only additive to mildly antagonistic interactions.

The strong synergy with dexamethasone is mechanistically compelling. Glucocorticoids kill lymphoid cells through receptors whose nuclear translocation and downstream signaling are potentiated by PI3K-AKT-mTOR inhibition, a finding previously documented in human B-cell acute lymphoblastic leukemia. The Colorado State results thus support the hypothesis that adding a dual PI3K/mTOR inhibitor to standard chemotherapy could deepen responses or sensitize resistant tumors, particularly in lymphoma, where the clinical reservoir of effective options is thin.

Importantly, the study went beyond cell culture to examine pathway activation in actual patients. Using tissue microarrays built from 118 lymph node samples collected from 84 dogs with spontaneous B-cell lymphoma, the researchers scored phosphorylated AKT and phosphorylated 4EBP1 by immunohistochemistry, employing both traditional manual Allred scoring and artificial intelligence-assisted whole-slide analysis with Visiopharm software to generate finer-grained H-scores. The two approaches correlated well, validating the use of machine learning tools for quantitative pathology in veterinary specimens. The phosphorylation signals proved highly variable from tumor to tumor, underscoring that not every canine B-cell lymphoma is driven by an equally active PI3K-AKT-mTOR pathway.

Two clinically meaningful correlations emerged. First, tumors with lower expression of major histocompatibility complex class II, a known adverse prognostic marker measured by flow cytometry, showed significantly higher levels of phosphorylated AKT, linking aggressive immune phenotype to stronger pathway activity. Second, samples taken after relapse following CHOP chemotherapy showed higher phosphorylated 4EBP1 than matched pre-treatment samples, a result that retained significance in paired manual scoring. However, no correlation was found between either phosphoprotein and progression-free interval, overall survival, WHO stage or substage, or flow cytometric immunophenotypic markers, and phosphorylated AKT did not rise in parallel with phosphorylated 4EBP1 in the relapse samples. The authors caution against overinterpreting these limited associations and suggest several possible explanations, including AKT phosphorylation at sites not detected by the assay, alternative 4EBP1 kinases such as PIM2 or RAS/MAPK signaling, or mutations downstream of AKT.

The study has clear limitations that its authors acknowledge. Only one cell line each was tested for lymphoma and leukemia, so the full heterogeneity of canine lymphoid malignancies, including T-cell lymphoma and acute lymphoblastic leukemia, remains unexplored. No washout experiments were performed to determine how long signaling stays suppressed after the drug is withdrawn, information that would be essential for designing oral dosing schedules. And the finding of elevated phosphorylated 4EBP1 without corresponding phosphorylated AKT in relapsed tumors awaits mechanistic confirmation. Nevertheless, the core message is clear: VDC597 collapses PI3K-AKT-mTOR signaling, kills lymphoid cancer cells in vitro at achievable concentrations, synergizes with dexamethasone, and may sensitize tumors to standard chemotherapy. As dogs with spontaneous diffuse large B-cell lymphoma are increasingly recognized as valuable models for human non-Hodgkin lymphoma, these results position dual PI3K/mTOR inhibition as a strategy worth advancing toward larger cell line panels, animal studies, and ultimately clinical trials in both species.

Subject of Research: Evaluation of the dual PI3K/mTOR inhibitor VDC597 against canine B-cell lymphoma and chronic lymphocytic leukemia cells in vitro, with immunohistochemical assessment of PI3K-AKT-mTOR pathway activation in spontaneous canine B-cell lymphoma.

Article Title: In vitro effects of the PI3K/mTOR dual-inhibitor, VDC597, in canine lymphoma and leukemia

Article References: Meuten, T., Brill, S. A., Brady, R. V., Farrell, K. B., Rose, B. J., Schlein, L. J., & Thamm, D. H. (2026). In vitro effects of the PI3K/mTOR dual-inhibitor, VDC597, in canine lymphoma and leukemia. Veterinary Oncology, 3(1), Article 13. https://doi.org/10.1186/s44356-026-00065-4

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00065-4

Keywords: canine lymphoma, canine leukemia, VDC597, PI3K, mTOR, AKT, 4EBP1, signal transduction, chemotherapy, immunohistochemistry, veterinary oncology, drug combination